U.S. Food and Drug Administration Approves Updated Label to Enable Faster Thawing of ADSTILADRIN® (nadofaragene firadenovec-vncg)
Ferring Pharmaceuticals has announced that the U.S. Food and Drug Administration has approved an important label update for ADSTILADRIN, introducing a faster and more efficient thawing process designed to simplify clinical preparation. The updated guidance allows healthcare providers to thaw the therapy using a controlled water-bath method in approximately 25 minutes, a notable improvement that enhances workflow efficiency in clinical settings.
This update reflects a growing emphasis on optimizing not only the clinical effectiveness of advanced therapies but also their real-world usability. For healthcare providers managing complex oncology treatments, preparation time and logistical considerations can significantly influence treatment delivery. By reducing thawing time, the revised protocol aims to streamline handling procedures, enabling medical teams to administer therapy more efficiently and potentially improve patient access.
ADSTILADRIN is a pioneering treatment in the field of urologic oncology. It is currently the first and only FDA-approved non-replicating intravesical gene therapy indicated for adults with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) who are unresponsive to Bacillus Calmette-Guérin (BCG) therapy. This includes patients with carcinoma in situ (CIS), with or without associated papillary tumors such as Ta or T1 lesions. The therapy represents a significant advancement for a patient population with limited treatment options, particularly for those who are not candidates for or wish to avoid radical cystectomy.
Bladder cancer remains a major public health concern in the United States, ranking as the sixth most common cancer. A substantial proportion of newly diagnosed cases—approximately 75%—are classified as NMIBC. While many patients initially respond to standard therapies such as BCG immunotherapy, a subset develops resistance, creating a need for alternative treatment approaches. ADSTILADRIN addresses this gap by leveraging gene therapy technology to deliver a therapeutic gene directly into the bladder, offering a novel mechanism of action compared to traditional treatments.
The newly approved thawing method is supported by data from a dedicated thawing and handling study. This research demonstrated that frozen vials of ADSTILADRIN remain stable when thawed in a water bath maintained at 25°C (77°F) for approximately 25 minutes. Importantly, the study confirmed that this accelerated thawing process does not compromise the product’s integrity or efficacy, ensuring that patients continue to receive a high-quality therapy.
ADSTILADRIN is supplied as a sterile frozen suspension and must be brought to room temperature before administration. Under the updated label, once thawing begins, the storage conditions remain unchanged. The therapy can be stored at room temperature for up to 24 hours or refrigerated at 2–8°C for up to seven days, including the thawing period. These flexible storage parameters further support clinical workflow by allowing providers to better plan and coordinate treatment schedules.
From a clinical perspective, the ability to prepare ADSTILADRIN more quickly has meaningful implications. Healthcare providers often operate in high-demand environments where time and resources are limited. Reducing preparation time can help optimize clinic operations, minimize delays, and improve the overall patient experience. For patients, particularly those undergoing repeated treatments, such efficiencies can translate into shorter wait times and more streamlined care.
Medical experts have highlighted the practical benefits of this update. Clinicians note that the shorter thawing time can enhance the feasibility of integrating ADSTILADRIN into routine practice, especially in busy urology and oncology centers. By simplifying preparation, the therapy becomes more accessible to a broader range of healthcare settings, potentially increasing its adoption and impact.
In addition to the new thawing method, ADSTILADRIN already offers several advantages that support patient-centered care. The therapy is administered once every three months, reducing the frequency of clinic visits compared to some alternative treatments. This dosing schedule can lessen the burden on patients, including travel requirements and time spent in healthcare facilities, while also easing demands on clinical staff.
Ferring Pharmaceuticals has emphasized that the label update is part of its broader commitment to continuously improving its therapies based on real-world needs. By focusing on both clinical outcomes and operational considerations, the company aims to ensure that innovative treatments can be delivered effectively in everyday practice. This approach reflects a growing trend in the pharmaceutical industry, where the success of a therapy is increasingly measured not only by its efficacy but also by its ease of use and integration into healthcare systems.
The introduction of a faster thawing process also underscores the importance of logistical innovation in the field of gene therapy. As advanced therapies become more prevalent, optimizing their handling and administration will be critical to maximizing their benefits. Improvements in preparation protocols can play a key role in overcoming practical barriers and enabling wider adoption.
Overall, the FDA’s approval of the updated label for ADSTILADRIN represents a meaningful step forward in enhancing the delivery of gene therapy for bladder cancer. By reducing preparation time and maintaining flexible storage conditions, the new protocol supports more efficient clinical workflows and improved patient access. For healthcare providers and patients alike, these enhancements contribute to a more streamlined and effective treatment experience, reinforcing ADSTILADRIN’s role as an important option in the management of high-risk NMIBC.
About Non-Muscle Invasive Bladder Cancer (NMIBC)
NMIBC is a form of bladder cancer that is found in the inner layer cells of the bladder and does not invade into or beyond the muscle wall.3 In the United States, bladder cancer is the sixth most common cancer,1 fourth among men,4 and it is estimated that there will be approximately 84,870 new cases of bladder cancer in the U.S. in 2025.4 Historically, 75% of bladder cancer presents as NMIBC.
In patients with high-risk NMIBC, intravesical BCG remains the first-line standard-of-care; however, approximately one third of patients with NMIBC will not respond to BCG therapy and 50% of those with an initial response will experience recurrence or progression of their disease.5 Current treatment options for BCG-unresponsive patients are very limited and National Comprehensive Cancer Network (NCCN) guidelines recommend cystectomy (partial or complete removal of the bladder).6
About ADSTILADRIN
ADSTILADRIN® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical non-replicating gene-therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (±Ta/T1). It is a non-replicating adenovirus vector-based therapy containing the gene interferon alfa-2b, administered locally as a monotherapy by catheter directly into the bladder once every three months.
The vector enters the cells of the bladder wall, releasing the active gene and causing the bladder’s cell walls to secrete high and transient local expression of interferon alfa-2b protein, a naturally occurring protein the body uses to fight cancer. This approach essentially turns the bladder wall cells into interferon microfactories, enhancing the body’s own natural defenses against the cancer.
Source Link:https://www.businesswire.com/
